These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19370547)

  • 41. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
    De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
    Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting μ-opioid receptor antagonist.
    Watari R; Matsuda A; Ohnishi S; Hasegawa H
    Drug Metab Pharmacokinet; 2019 Apr; 34(2):126-133. PubMed ID: 30770183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
    Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
    J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
    Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF
    Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein.
    Adachi Y; Suzuki H; Sugiyama Y
    Pharm Res; 2001 Dec; 18(12):1660-8. PubMed ID: 11785684
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
    Elsby R; Surry DD; Smith VN; Gray AJ
    Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation.
    Chen C; Pollack GM
    Pharm Res; 1999 Feb; 16(2):296-301. PubMed ID: 10100317
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential opioid agonist regulation of the mouse mu opioid receptor.
    Blake AD; Bot G; Freeman JC; Reisine T
    J Biol Chem; 1997 Jan; 272(2):782-90. PubMed ID: 8995364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
    Dahan A; Sabit H; Amidon GL
    AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Negative relationship between morphine analgesia and P-glycoprotein expression levels in the brain.
    Hamabe W; Maeda T; Kiguchi N; Yamamoto C; Tokuyama S; Kishioka S
    J Pharmacol Sci; 2007 Dec; 105(4):353-60. PubMed ID: 18071274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice.
    Coles LD; Lee IJ; Hassan HE; Eddington ND
    J Pharm Sci; 2009 Aug; 98(8):2832-46. PubMed ID: 19116954
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.
    Lacher SE; Gremaud JN; Skagen K; Steed E; Dalton R; Sugden KD; Cardozo-Pelaez F; Sherwin CM; Woodahl EL
    J Pharmacol Exp Ther; 2014 Feb; 348(2):336-45. PubMed ID: 24297779
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation.
    Bauer B; Yang X; Hartz AM; Olson ER; Zhao R; Kalvass JC; Pollack GM; Miller DS
    Mol Pharmacol; 2006 Oct; 70(4):1212-9. PubMed ID: 16837625
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Jiang B; Yan LJ; Wu Q
    DNA Cell Biol; 2019 May; 38(5):485-490. PubMed ID: 30977678
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice.
    Leusch A; Volz A; Müller G; Wagner A; Sauer A; Greischel A; Roth W
    Eur J Pharm Sci; 2002 Aug; 16(3):119-28. PubMed ID: 12128165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The molecular interaction of a copper chelate with human P-glycoprotein.
    Ghosh RD; Chakraborty P; Banerjee K; Adhikary A; Sarkar A; Chatterjee M; Das T; Choudhuri SK
    Mol Cell Biochem; 2012 May; 364(1-2):309-20. PubMed ID: 22258826
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques.
    On NH; Chen F; Hinton M; Miller DW
    Pharm Res; 2011 Oct; 28(10):2505-15. PubMed ID: 21598079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
    Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
    Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in dipole membrane potential at the mouse blood-brain barrier enhance the transport of 99mTechnetium Sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2.
    Cattelotte J; Tournier N; Rizzo-Padoin N; Schinkel AH; Scherrmann JM; Cisternino S
    J Neurochem; 2009 Feb; 108(3):767-75. PubMed ID: 19067785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.